Table 1.
Clinical characteristics of patients by timing of CIN in all and landmark groups with metastatic colon cancer received mFOLFOX6 as first-line treatment
| All patients | Landmark patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Early-onset | Late-onset | Absence | P value | Early-onset | Late-onset | Absence | P value | |
| N = 141 | N = 40 | N = 109 | N = 130 | N = 32 | N = 70 | |||
| Age(years) | ||||||||
| Median(range) | 57 (29–74) | 57 (37–73) | 58 (33–76) | 0.560 | 58 (49–62) | 57.5 (54–61.5) | 57 (53–62) | 0.326 |
| Height(cm) | ||||||||
| Median(range) | 168 (153–179) | 170 (153–184) | 168 (154–180) | 0.624 | 168 (165–170) | 170 (160–176) | 169 (165–170) | 0.684 |
| Weight(kg) | ||||||||
| Median(range) | 67 (47–85) | 72 (53–97) | 64 (50–88) | 0.058 | 62 (58–70) | 66 (64–69) | 73 (68–80) | 0.043 |
| Relative dose intensity | ||||||||
| Median | 0.86 (0.73–0.89) | 0.88 (0.75–0.91) | 0.90 (0.78–0.93) | 0.106 | 0.85 (0.71–0.87) | 0.89 (0.74–0.90) | 0.88 (0.78–0.91) | 0.215 |
| Gender | ||||||||
| male | 48 | 17 | 36 | 0.752 | 45 | 15 | 31 | 0.214 |
| female | 93 | 23 | 73 | 85 | 17 | 39 | ||
| KPS | ||||||||
| 90 | 131 | 39 | 103 | 0.216 | 121 | 31 | 66 | 0.069 |
| 70–80 | 10 | 1 | 6 | 9 | 1 | 4 | ||
| Pathological differentiation | ||||||||
| Well-moderate | 121 | 25 | 83 | 0.039 | 114 | 21 | 52 | 0.283 |
| Poor | 20 | 15 | 26 | 16 | 11 | 18 | ||
| Liver metastasis | ||||||||
| present | 110 | 27 | 85 | 0.502 | 102 | 21 | 55 | 0.368 |
| absent | 31 | 13 | 24 | 28 | 11 | 15 | ||
| Severity of CIN | ||||||||
| Absence | 0 | 0 | 109 | <0.01 | 0 | 0 | 70 | <0.01 |
| Mild | 107 | 25 | 0 | 98 | 22 | 0 | ||
| Sever | 34 | 15 | 0 | 32 | 10 | 0 | ||
Tests used: Wilcoxon and Pearson’s chi-square tests